{
    "organizations": [],
    "uuid": "88f7c64b0c4e11bddef8597df9d1de780bad22ce",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-nuuvera-amends-arrangement-agrees/brief-nuuvera-amends-arrangement-agrees-to-acquire-remaining-interest-in-avanti-rx-analytics-idUSASB0C6DL",
    "ord_in_thread": 0,
    "title": "BRIEF-Nuuvera Amends Arrangement Agrees To Acquire Remaining Interest In Avanti Rx Analytics",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 20 (Reuters) - Nuuvera Inc:\n* NUUVERA AMENDS ARRANGEMENT; AGREES TO ACQUIRE REMAINING INTEREST IN AVANTI RX ANALYTICS\n* NUUVERA AMENDS ARRANGEMENT; AGREES TO ACQUIRE REMAINING INTEREST IN AVANTI RX ANALYTICS\n* ‍TOTAL CONSIDERATION FOR AVANTI TRANSACTION IS EXPECTED TO BE APPROXIMATELY $43 MILLION​\n* DEAL CONSIDERATION HAS BEEN REDUCED TO $0.60 IN CASH, 0.3546 OF AN APHRIA SHARE FOR EACH NUUVERA SHARE Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-20T21:23:00.000+02:00",
    "crawled": "2018-02-21T21:30:39.004+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "nuuvera",
        "inc",
        "nuuvera",
        "amends",
        "arrangement",
        "agrees",
        "acquire",
        "remaining",
        "interest",
        "avanti",
        "rx",
        "analytics",
        "nuuvera",
        "amends",
        "arrangement",
        "agrees",
        "acquire",
        "remaining",
        "interest",
        "avanti",
        "rx",
        "analytics",
        "consideration",
        "avanti",
        "transaction",
        "expected",
        "approximately",
        "deal",
        "consideration",
        "reduced",
        "cash",
        "aphria",
        "share",
        "nuuvera",
        "share",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}